Literature DB >> 21426045

Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.

Valerie Vivat Hannah1, C Atmanene, D Zeyer, A Van Dorsselaer, Sarah Sanglier-Cianférani.   

Abstract

The success of early drug-discovery programs depends on the adequate combination of complementary and orthogonal technologies allowing hit/lead compounds to be optimized and improve therapeutic activity. Among the available biophysical methods, native MS recently emerged as an efficient method for compound-binding screening. Native MS is a highly sensitive and accurate screening technique. This review provides a description of the general approach and an overview of the possible characterization of ligand-binding properties. How native MS supports structure- and fragment-based drug research will also be discussed, with examples from the literature and internal developments. Native MS shows strong potential for in-depth characterization of ligand-binding properties. It is also a reliable screening technique in drug-discovery processes.

Mesh:

Substances:

Year:  2010        PMID: 21426045     DOI: 10.4155/fmc.09.141

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  17 in total

1.  Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors.

Authors:  Rongshi Li; Mathew P Martin; Yan Liu; Binglin Wang; Ronil A Patel; Jin-Yi Zhu; Nan Sun; Roberta Pireddu; Nicholas J Lawrence; Jiannong Li; Eric B Haura; Shen-Shu Sung; Wayne C Guida; Ernst Schonbrunn; Said M Sebti
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 2.  The emerging role of native mass spectrometry in characterizing the structure and dynamics of macromolecular complexes.

Authors:  Elisabetta Boeri Erba; Carlo Petosa
Journal:  Protein Sci       Date:  2015-03-31       Impact factor: 6.725

Review 3.  Biophysics in drug discovery: impact, challenges and opportunities.

Authors:  Jean-Paul Renaud; Chun-Wa Chung; U Helena Danielson; Ursula Egner; Michael Hennig; Roderick E Hubbard; Herbert Nar
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

Review 4.  Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.

Authors:  Cedric E Bobst; Igor A Kaltashov
Journal:  Curr Pharm Biotechnol       Date:  2011-10       Impact factor: 2.837

5.  Monitoring the dynamics of monomer exchange using electrospray mass spectrometry: the case of the dimeric glucosamine-6-phosphate synthase.

Authors:  Guillaume Chevreux; Cédric Atmanene; Philippe Lopez; Jamal Ouazzani; Alain Van Dorsselaer; Bernard Badet; Marie-Ange Badet-Denisot; Sarah Sanglier-Cianférani
Journal:  J Am Soc Mass Spectrom       Date:  2011-01-15       Impact factor: 3.109

6.  The Growing Importance of Chirality in 3D Chemical Space Exploration and Modern Drug Discovery Approaches for Hit-ID: Topical Innovations.

Authors:  Ilaria Proietti Silvestri; Paul J J Colbon
Journal:  ACS Med Chem Lett       Date:  2021-07-16       Impact factor: 4.632

Review 7.  High-Resolution Native Mass Spectrometry.

Authors:  Sem Tamara; Maurits A den Boer; Albert J R Heck
Journal:  Chem Rev       Date:  2021-08-20       Impact factor: 72.087

Review 8.  The multifaceted roles of mass spectrometric analysis in nucleic acids drug discovery and development.

Authors:  Thomas Kenderdine; Dan Fabris
Journal:  Mass Spectrom Rev       Date:  2021-12-23       Impact factor: 9.011

9.  A ligand-observed mass spectrometry approach integrated into the fragment based lead discovery pipeline.

Authors:  Xin Chen; Shanshan Qin; Shuai Chen; Jinlong Li; Lixin Li; Zhongling Wang; Quan Wang; Jianping Lin; Cheng Yang; Wenqing Shui
Journal:  Sci Rep       Date:  2015-02-10       Impact factor: 4.379

10.  Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers.

Authors:  Chendi Niu; Yi Du; Igor A Kaltashov
Journal:  Int J Mass Spectrom       Date:  2021-02-14       Impact factor: 1.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.